Massimiliano Fabbiani

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Topics

Methicillin Resistant Staphylococcus Aureus

Human Immunodeficiency Virus

Clinical Practice

Top Venues

Diagnostics (Basel, Switzerland)

Antibiotics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Paola Tramonti Fantozzi, Luca Ceccarelli, Davide Petri, Erica De Vita, Antonello Agostini, Piero Colombatto, Cristina Stasi, Barbara Rossetti, Maurizia Brunetto, Lidia Surace, Antonio Salvati, Alessia Calì, Danilo Tacconi, Claudia Bianco, David Redi, Massimiliano Fabbiani, Francesca Panza, Sauro Luchi, Sara Modica, Sara Moneta, Sarah Iacopini, Cesira Nencioni, Silvia Chigiotti, Giulia Ottaviano, Anna Linda Zignego, Pierluigi Blanc, Piera Pierotti, Elisa Mariabelli, Roberto Berni, Caterina Silvestri, Lara Tavoschi
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID-19 pandemic. Journal of viral hepatitis (2024)
Francesca Lombardi, Alessia Sanfilippo, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Enrica Tamburrini, Simona Di Giambenedetto
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study. The Journal of antimicrobial chemotherapy (2023)
Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Ferdinando Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. Viruses 15 (5) (2023)
Francesca Panza, Francesca Montagnani, Gennaro Baldino, Cosimo Custoza, Mario Tumbarello, Massimiliano Fabbiani
Primary Cutaneous Cryptococcosis in an Immunocompetent Patient: Diagnostic Workflow and Choice of Treatment. Diagnostics (Basel, Switzerland) 13 (19) (2023)
Francesca Panza, Fabio Fiorino, Gabiria Pastore, Lia Fiaschi, Mario Tumbarello, Donata Medaglini, Annalisa Ciabattini, Francesca Montagnani, Massimiliano Fabbiani
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? Microorganisms 11 (10) (2023)
Barbara Rossetti, Massimiliano Fabbiani, Domenico Di Carlo, Francesca Incardona, Ana Abecasis, Perpetua Gomes, Anna Maria Geretti, Carole Seguin-Devaux, Federico Garcia, Rolf Kaiser, Sara Modica, Adrian Shallvari, Anders Sönnerborg, Maurizio Zazzi, null null
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. HIV medicine 23 (7) (2022)
Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi, Filippo Lagi, Alessandra Latini, Gabriella d'Ettorre, Letizia Oreni, Paolo Fusco, Amedeo Ferdinando Capetti, Massimiliano Fabbiani, Andrea Giacomelli, Alessandro Grimaldi, Giordano Madeddu, Gaetana Sterrantino, Cristina Mussini, Simona Di Giambenedetto
Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. Viruses 14 (1) (2022)
Francesca Lombardi, Rosalba Ricci, Simone Belmonti, Massimiliano Fabbiani, Alberto Borghetti, Gianmaria Baldin, Arturo Ciccullo, Enrica Tamburrini, Elena Visconti, Sanguinetti Maurizio, Simona Di Giambenedetto
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. Diagnostics (Basel, Switzerland) 11 (7) (2021)
Barbara Rossetti, Valentina Borgo, Arianna Emiliozzi, Marta Colaneri, Giacomo Zanelli, Miriana d'Alessandro, Davide Motta, Laura Maiocchi, Francesca Montagnani, Maria Cristina Moioli, Chiara Baiguera, Margherita Sambo, Teresa Chiara Pieri, Pietro Valsecchi, Raffaele Bruno, Massimo Puoti, Massimiliano Fabbiani
Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. Diagnostics (Basel, Switzerland) 12 (1) (2021)
Massimiliano Fabbiani, Barbara Rossetti, Arturo Ciccullo, Letizia Oreni, Filippo Lagi, Luigi Celani, Manuela Colafigli, Andrea De Vito, Mazzitelli Maria, Alex Dusina, Miriam Durante, Francesca Montagnani, Stefano Rusconi, Amedeo Capetti, Gaetana Sterrantino, Gabriella D'Ettorre, Simona Di Giambenedetto, null null
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. HIV medicine 22 (9) (2021)
Massimiliano Fabbiani, Andrea Lombardi, Marta Colaneri, Paolo Del Poggio, Paolo Perini, Roberta D'Ambrosio, Elisabetta Degasperi, Clara Dibenedetto, Alessia Giorgini, Luisa Pasulo, Franco Maggiolo, Francesco Castelli, Paola Brambilla, Ombretta Spinelli, Tiziana Re, Ana Lleo, Mariagrazia Rumi, Caterina Uberti-Foppa, Alessandro Soria, Alessio Aghemo, Pietro Lampertico, Chiara Baiguera, Monica Schiavini, Stefano Fagiuoli, Raffaele Bruno, null null
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. Journal of viral hepatitis 28 (3) (2021)
Barbara Rossetti, Massimiliano Fabbiani, Domenico Di Carlo, Francesca Incardona, Ana Abecasis, Perpetua Gomes, Anna Maria Geretti, Carole Seguin-Devaux, Federico Garcia, Rolf Kaiser, Sara Modica, Adrian Shallvari, Anders Sönnerborg, Maurizio Zazzi, null null
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. The Journal of antimicrobial chemotherapy 76 (9) (2021)
Alberto Borghetti, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Alex Dusina, Massimiliano Fabbiani, Stefano Rusconi, Maurizio Zazzi, Cristina Mussini, Simona Di Giambenedetto
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. Open forum infectious diseases 8 (7) (2021)
Stefano di Bella, Bojana Beović, Massimiliano Fabbiani, Michael Valentini, Roberto Luzzati
Antimicrobial Stewardship: From Bedside to Theory. Thirteen Examples of Old and More Recent Strategies from Everyday Clinical Practice. Antibiotics (Basel, Switzerland) 9 (7) (2020)
Roberta Maria Antonello, Luigi Principe, Alberto Enrico Maraolo, Valentina Viaggi, Riccardo Pol, Massimiliano Fabbiani, Francesca Montagnani, Antonio Lovecchio, Roberto Luzzati, Stefano di Bella
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics (Basel, Switzerland) 9 (8) (2020)
Gianluca Sambataro, Mauro Giuffré, Domenico Sambataro, Andrea Palermo, Giovanna Vignigni, Roberto Cesareo, Nunzio Crimi, Sebastiano Emanuele Torrisi, Carlo Vancheri, Lorenzo Salvatore Malatino, Michele Colaci, Nicoletta Del Papa, Francesca Pignataro, Erik Roman-Pognuz, Massimiliano Fabbiani, Francesca Montagnani, Chiara Cassol, Lorenzo Cavagna, Valentina Zuccaro, Verena Zerbato, Cristina Maurel, Roberto Luzzati, Stefano di Bella
The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. Diagnostics (Basel, Switzerland) 10 (9) (2020)
Massimiliano Fabbiani, Nicoletta Ciccarelli, Valeria Castelli, Alessandro Soria, Alberto Borghetti, Elisa Colella, Davide Moschese, Manuela Valsecchi, Arianna Emiliozzi, Andrea Gori, Andrea De Luca, Alessandra Bandera, Simona Di Giambenedetto
Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients. Journal of neurovirology 25 (6) (2019)
Francesca Lombardi, Simone Belmonti, Alberto Borghetti, Arturo Ciccullo, Gianmaria Baldin, Roberto Cauda, Massimiliano Fabbiani, Simona Di Giambenedetto
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV research & clinical practice (2019)